Apheresis in the treatment of cholesterol embolic disease

Midori Hasegawa, Satoshi Sugiyama

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Cholesterol embolic disease is a devastating complication of atherosclerosis. Universally recommended treatment is lacking thus far. Recent data suggest that a therapeutic protocol aimed at specifically combating three causes of mortality, recurrent bouts of cholesterol embolism, cardiac failure, and cahexia, were associated with a favorable clinical outcome. As for drug therapy, corticosteroid has been reported to be beneficial in reducing local and general inflammatory responses. Concerning apheresis, combined therapy consisting of plasma exchange and low to intermediate-dose corticosteroid therapy has been shown to be effective in multivisceral cholesterol embolism. Low density lipoprotein (LDL) apheresis has been reported to be beneficial for cholesterol embolism-induced damage to the skin and brain.

Original languageEnglish
Pages (from-to)435-438
Number of pages4
JournalTherapeutic Apheresis
Issue number4
Publication statusPublished - 08-2003

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Apheresis in the treatment of cholesterol embolic disease'. Together they form a unique fingerprint.

Cite this